1. Seromycin® is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.
2. Seromycin® may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially Enterobacter spp. And Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria.
3. Use of Seromycin® in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.

The current product insert for Seromycin® is available on this web site and provides complete information about the clinical pharmacology, indications, contraindications, warnings, precautions, adverse reactions, overdosage treatment, dosage and administration, and how the drug is supplied.

The current supply of Seromycin® was manufactured by Eli Lilly and Company and transferred to the control of the Chao Center in December, 2007, along with the registered trademark and responsibility for the manufacture and sale of this prescription drug in the United States and its territories.   Eli Lilly and Company was the original manufacturer.  Personnel at The Chao Center were trained by Lilly employees to manufacture Seromycin using the same process and procedures that had been established and approved by the FDA during the fifty-two years since the original ‘Accelerated Antibiotic Drug Application’ was issued in 1956.  In March, 2008, The Chao Center received permission from the government of Canada to sell directly to physicians in Canada under the Health Canada Special Access Program. In July, 2008, The Chao Center received approval from the FDA to manufacture Seromycin under its own label using the same process transferred by Eli Lilly and Company.